Open an account

Fresenius Medical Care AG

FMS · XETRA

$22.68+$0.45 (+2.02%)TodayMarket closed ·
Prev close $22.23

About FMS

Fresenius Medical Care AG engages in the provision of products and services for individuals with renal diseases. The company is headquartered in Bad Homburg Vor Der Hohe, Hessen and currently employs 109,698 full-time employees. The firm provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD) and offers other extracorporeal therapies, as well as other healthcare services. The company has two operating segments such as care delivery segment which consolidates the global health care services business and care enablement segment includes research and development (R&D), manufacturing, supply chain, and commercial operations. The company develops and manufactures health care products, which includes dialysis and non-dialysis products. Such as hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment. Its non-dialysis products include acute cardiopulmonary and apheresis products. The company owns, operates, or manages dialysis clinics sells products to other dialysis providers.

Employees
108,165
Headquarters
Bad Homburg vor der Hohe, Hessen
Listed
Oct 2, 1996
Sector
Health Care
Industry
Health Care Providers & Services
Website
freseniusmedicalcare.com

FMS key statistics

Market cap
10.41B
Price-earnings ratio
5.88
Dividend yield
3.84%
Average volume
1.31M
Volume
733.46K
Open price
$22.42
High today
$22.73
Low today
$22.27
52 Week high
$27.40
52 Week low
$20.02

Fresenius Medical Care AG (FMS) at a glance

As of Oct 23, 2026, Fresenius Medical Care AG (FMS) shares are priced at $22.68, giving the company a market cap of 10.41B, a price-to-earnings ratio of 5.88 and a dividend yield of 3.84%.

Today the stock has traded between $22.27 and $22.73. The current price is 1.8% above the day's low and 0.2% below its high.

Volume so far is 733.46K shares, below the average of 1.31M shares a day.

Over the past year Fresenius Medical Care AG has ranged from $20.02 to $27.40, and now sits 36% of the way up that range.

Fresenius Medical Care AG met or beat analyst EPS estimates in 7 of the last 8 quarters. In Q2 FY26 it reported $1.13 per share against an estimate of $1.05.

The average analyst price target is $23.62, 4.2% above the current price, from 2 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

0%of 2 analyst ratings say Buy
  • Buy0.0%
  • Hold100.0%
  • Sell0.0%
Price target · 24 analystsAvg $23.62
Low
$12.13
Now
$22.68
High
$37.68

FMS earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 7 of the last 8 quarters, by 20.0% on average.

  1. Q3 FY24: reported $0.82 per share against an estimate of $0.6518
  2. Q4 FY24: reported $0.91 per share against an estimate of $0.7911
  3. Q1 FY25: reported $0.84 per share against an estimate of $0.6605
  4. Q2 FY25: reported $0.91 per share against an estimate of $0.7921
  5. Q3 FY25: reported $1.10 per share against an estimate of $0.9635
  6. Q4 FY25: reported $1.44 per share against an estimate of $1.06
  7. Q1 FY26: reported $0.91 per share against an estimate of $0.9928
  8. Q2 FY26: reported $1.13 per share against an estimate of $1.05

FMS news

  • Press releasePRNewswire

    Fresenius Medical Care Brings Kidney Care Innovation to Critical Care Patients with U.S. Launch of multiFiltratePRO™

  • Press releasePRNewswire

    Fresenius Medical Care presents new evidence and innovations advancing kidney care at ASN Kidney Week 2026

  • Press releasePRNewswire

    Shervin J. Korangy appointed CEO of Fresenius Medical Care to lead the next phase of strategic development and long-term profitable growth

  • Fresenius Medical Care Shares Halted, News Pending

  • Vandana Singh

    Fresenius Medical Care Refines China Strategy With Targeted Product Focus

  • Press releasePRNewswire

    Fresenius Medical Care Refines China Commercial Strategy with a Focus on Long-Term Growth and Market Leadership

  • Vandana Singh

    FDA Slams Fresenius Over Leaking Dialysis Bags, Warns of Potentially Life-Threatening Risk

  • Press releasePRNewswire

    Fresenius Medical Care Announces Publication of a Multinational Real-World Evidence Study Associating High-Volume Hemodiafiltration with Lower Mortality Risk Than Conventional Hemodialysis

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.